Startups, BioPharma

Gene therapy startup Dimension Therapeutics files for $115M IPO

Cambridge gene therapy startup Dimension Therapeutics just filed for a $115 million IPO. It will kick off Phase 1/2 trials for its hemophilia B treatment later this year.

Cambridge gene therapy player Dimension Therapeutics just filed for a $115 million IPO – right on the heels of an FDA sanction that it begin clinical trials for its hemophilia B treatment.

The company raised $65 million Series B round from a group of crossover investors just this past April; investors have since been chomping at the bit for an IPO.

Dimension’s pipeline is rare disease-heavy and includes gene therapies for hemophilia A, ornithine transcarbamylase deficiency, and glycogen storage disease type la. Its hemophilia B treatment has an orphan designation and was fast-tracked by the FDA in earlier this month. The company uses an adeno-associated virus (AAV) vectors to transfer genetic material into liver cells in particular.

Several biotech startups are using hemophilia as an early target for gene therapy. Dimension plans to launch Phase 1/2 trials for its hemophilia B candidate, DTX101, as well as launch IND-enabling studies for its hemophilia A therapy, by the close of this year. Dimension’s hemophilia A program is partnered out with Bayer, for which it’s received $27 million. It’ll move into IND-enabling studies for treating OTC deficiency by the second half of 2016, the company’s S-1 filing with the SEC said.

[IMAGE: Freedigitalphotos user dream designs]

 

Shares0
Shares0